argus

Zydus Lifesciences Limited

NSE: ZYDUSLIFEINE010B010271,16,952 Cr

Timeline

Time (IST)TypeMEventSrc
01 Sept, 10:59 amother1Zydus Lifesciences provides general updates to the exchange without disclosing any specific financial or operational material events.nse
31 Aug, 10:46 amZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
31 Aug, 10:43 amother2Zydus announces positive topline results from a completed Phase II(b) clinical trial of Saroglitazar Mg in MASH.nse
26 Aug, 11:15 amZydus Lifesciences Ltd - 532321 - Incorporation Of A Wholly Owned Subsidiary In Gift City, Gandhinagar, Gujaratbse
26 Aug, 11:12 amZydus Lifesciences Limited has informed the Exchange about General Updatesnse
25 Aug, 05:40 pmZydus Lifesciences Ltd - 532321 - ESG Ratingbse
25 Aug, 05:02 pmZydus Lifesciences Limited has informed the Exchange about General Updatesnse
24 Aug, 07:34 pmZydus Lifesciences Limited has informed the Exchange regarding 'Disclosure under SEBI (Prohibition of Insider Trading) Regulations, 2015'.nse
23 Aug, 12:39 pmZydus Lifesciences Limited has informed the Exchange about Investor Presentationnse
23 Aug, 12:33 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Investor Presentationbse
21 Aug, 06:01 pmZydus Lifesciences Ltd - 532321 - ESG Ratingbse
21 Aug, 05:57 pmZydus Lifesciences Limited has informed the Exchange about General Updatesnse
21 Aug, 01:55 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
21 Aug, 01:52 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated August 21, 2026, titled "Zydus announces final approval from the USFDA for Ascorbic Acid Injection with 180-Days CGT exclusivity".nse
18 Aug, 02:59 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Earnings Call Transcriptbse
18 Aug, 02:55 pmZydus Lifesciences Limited has informed the Exchange about Transcriptnse
11 Aug, 08:28 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Change in Directoratebse
11 Aug, 08:08 pmZydus Lifesciences Limited has informed the Exchange regarding Change in Director(s) of the company.nse
11 Aug, 07:52 pmZydus Lifesciences Limited has informed the Exchange about Link of Recordingnse
11 Aug, 07:46 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcomebse
11 Aug, 07:07 pmZydus Lifesciences Limited has informed the Exchange regarding 'Reporting of violation of Code of Conduct under SEBI (Prohibition of Insider Trading) Regulations, 2015'.nse
11 Aug, 06:52 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated August 11, 2026, titled "Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency- Associated Lung Disease (AATD-LD)".nse
11 Aug, 01:30 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated August 11, 2026, titled "Press Release".nse
11 Aug, 01:29 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
11 Aug, 01:27 pmZydus Lifesciences Limited has informed the Exchange about Investor Presentationnse
11 Aug, 01:27 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Investor Presentationbse
11 Aug, 01:24 pmZydus Lifesciences Ltd - 532321 - Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended On June 30, 2026bse
11 Aug, 01:24 pmZydus Lifesciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.nse
11 Aug, 01:22 pmZydus Lifesciences Ltd - 532321 - Unaudited Financial Results For The Quarter Ended On June 30, 2026bse
10 Aug, 03:23 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
10 Aug, 03:19 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated August 10, 2026, titled "Zydus launches REVAHALE , India s first once-daily nebulised LAMA for COPD".nse
04 Aug, 03:12 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
04 Aug, 03:08 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated August 04, 2026, titled "Zydus announces Final Approval from the USFDA for Indocyanine Green for Injection with 180-Days CGT exclusivity".nse
01 Aug, 02:42 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated August 01, 2026, titled "Zydus receives EIR from the USFDA for its injectable facility with VAI classification".nse
01 Aug, 02:38 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
29 Jul, 12:30 pmZydus Lifesciences Ltd - 532321 - Receipt Of Order From The Office Of The Superintendent Of Stamps, Gandhinagar, Gujaratbse
29 Jul, 12:27 pmZydus Lifesciences Limited has informed the Exchange about General Updatesnse
25 Jul, 04:08 pmZydus Lifesciences Limited has informed the Exchange about Disruption of Operationsnse
25 Jul, 04:04 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Strikes /Lockouts / Disturbancesbse
23 Jul, 10:07 amZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
23 Jul, 10:04 amZydus Lifesciences Limited has informed the Exchange regarding a press release dated July 23, 2026, titled "Zydus receives approval for Phase III trial of Desidustat in patients with Sickle Cell Disease, to be conducted in collaboration with ICMR".nse
20 Jul, 12:54 pmZydus Lifesciences Ltd - 532321 - Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter Ended On June 30, 2026.bse
15 Jul, 08:34 amZydus Lifesciences Ltd - 532321 - Reply To The Clarification Sought From The Companybse
14 Jul, 08:30 pmThe Exchange has sought clarification from Zydus Lifesciences Limited with respect to recent news item captioned Delhi HC Temporarily Restricts Supply Of Zydus Cancer Drug Ikra In AbbVie Patent Dispute. The response from the Company is attached.nse
14 Jul, 05:46 pmThe Exchange has sought clarification from Zydus Lifesciences Limited with respect to recent news item captioned Delhi HC Temporarily Restricts Supply Of Zydus Cancer Drug Ikra In AbbVie Patent Dispute. The response from the Company is awaited.nse
10 Jul, 02:02 pmZydus Lifesciences Ltd - 532321 - Reg. 34 (1) Annual Report.bse
03 Jul, 12:21 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated July 03, 2026, titled "Zydus signs MoU with Apollo Hospitals to expand access to the Shield Multi-Cancer Detection test (MCD) in India".nse
03 Jul, 12:16 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
29 Jun, 02:36 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Updates on Acquisitionbse
29 Jun, 02:31 pmZydus Lifesciences Limited has informed the Exchange about General Updatesnse